29

June

FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma

On June 22, 2020, the Food and Drug Administration granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. Learn more

Product Information

Prescribing Information

Relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) Treatment Protocol Assessment

Victoria

Victoria has blogged 1160 posts